Sanofi-Aventis strengthens cancer portfolio with BiPar acquisition
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to acquire the private US biopharmaceutical company BiPar Sciences, which develops novel tumour-selective approaches for the treatment of various types of cancer.